KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

J Clin Oncol · 2026-Jan-20 · PMID 41370738

Panel C质量警告待 EXE 对齐验证

TTNT

FIG 2. (A) PFS as assessed by IRC, (B) EFS, and (C) TTNT in the intention-to-treat population. a HR and corresponding 95% CI were determined by using stratified Cox proportional hazard model. b P value was determined by using stratified log-rank test. EFS, event-free survival; HR, hazard ratio; IRC, independent review committee; PFS, progression-free survival; PomDex, pomalidomide and dexamethasone; TTNT, time to next treatment; VenDex, venetoclax and dexamethasone.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.79
质量通过否
预期曲线2
实际曲线1
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证12026-07-23T17:02:22+00:00